AVXL vs LIN · $247.4M cap vs P/E 34, rev $18.07B
Anavex Life Sciences Corp (AVXL) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Anavex Life Sciences Corp (AVXL) is a biotechnology company listed on NASDAQ.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
AVXL does not have a complete income-statement cache yet.
Latest reported LIN revenue for 2026-06-30 was $18.07B. Net income was $3.79B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
AVXL currently screens at market cap $247.4M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the AVXL and LIN stock pages for the full models.
Not investment advice.